Summary
This Opinion & Order from the U.S. District Court for the Eastern District of Virginia addresses a defendant's motion to realign the parties in a patent dispute. Applying the Fourth Circuit's "principal purpose" test, the court determined that patent infringement is the primary issue in controversy rather than the declaratory judgment action initially filed by BioNTech and Pfizer. Consequently, the court granted the motion to realign CureVac as the plaintiff and BioNTech and Pfizer as defendants to simplify the trial presentation and align the burdens of proof with the substantive claims.
Topics
Practice areas
Questions Presented
- Whether the district court should grant the motion to realign the parties under the ‘principal purpose’ test.
Holdings
- The court grants the motion, realigning the parties so that CureVac is the plaintiff and BioNTech and Pfizer are defendants.
Key quotations
“The principal purpose of this case is to decide whether BioNTech and Pfizer infringed CureVac’s patents. And a jury will understand BioNTech and Pfizer’s invalidity arguments better if that issue is framed as an affirmative defense to infringement liability.”
“The Motion to Realign Parties submitted by Defendant and Counterclaimant CureVac SE and Counterclaimant CureVac Manufacturing GmbH (ECF No. 448) is GRANTED.”
Factual background
The plaintiffs BioNTech and Pfizer sued for declaratory judgment that they did not infringe CureVac’s patents. CureVac responded with counterclaims alleging infringement and later added invalidity claims. The parties later sought a realignment of parties to reflect that the primary issue was infringement.
Procedural history
BioNTech and Pfizer filed a declaratory‑judgment complaint asserting non‑infringement of CureVac patents. CureVac counterclaimed for infringement and later added invalidity defenses. After extensive briefing the parties moved to realign the parties so that CureVac would be the plaintiff and BioNTech/Pfizer the defendants.